Paul Hudson, Sanofi CEO (Cyril Marcilhacy/Bloomberg via Getty Images)
FDA sidelines Paul Hudson's $3.7B MS drug after establishing link to liver damage
One of Sanofi CEO Paul Hudson’s top picks in the pipeline — picked up in a $3.7 billion buyout 2 years ago — has just been sidelined …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
